半肾
精华
|
战斗力 鹅
|
回帖 0
注册时间 2020-5-25
|
本帖最后由 Sutikku 于 2024-5-10 13:31 编辑
新抗原好像是等到秋季再更新
As the virus is expected to continue to evolve from JN.1, the TAG-CO-VAC advises the use of a monovalent JN.1 lineage as the antigen in future formulations of COVID-19 vaccines.
由于预计病毒将继续从JN.1进化而来,TAG-CO-VAC建议在未来的COVID-19疫苗配方中使用单价JN.1谱系作为抗原。
Novavax plans to be ready to deliver our JN.1 protein-based non-mRNA COVID-19 vaccine globally this fall.
Novavax计划于今年秋季在全球范围内提供我们的JN.1蛋白质非mRNA COVID-19疫苗。
Today, the FDA’s Center for Biologics Evaluation and Research (CBER) is announcing that the May 16, 2024, meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) is being rescheduled to June 5, 2024. The meeting, at which the Committee will discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines, is being moved to a later date to allow for additional time to obtain surveillance data and other information on recently circulating strains and to ensure that committee members will have more up-to-date information when making their recommendations.
今天,美国食品药品监督管理局生物制品评估与研究中心(CBER)宣布,2024年5月16日的疫苗和相关生物制品咨询委员会(VRBPAC)会议将重新安排到2024年6月5日。委员会将在会议上讨论2024-2025年新冠肺炎疫苗配方中所含毒株的选择并提出建议,会议将推迟到晚些时候举行,以便有更多时间获得监测数据和最近传播的毒株的其他信息,并确保委员会成员在提出建议时获得更多最新信息。 |
|